Anti-cyclic citrullinated peptide antibody up to 200RU/ml is more serious, normally less than 5RU/ml.
Anti-cyclic citrullinated peptide antibody, also known as CCP antibody, is an antibody with high specificity for diagnosing rheumatoid arthritis, and the sensitivity can reach 70%~80%, and the positive rate of patients with rheumatoid arthritis in the early stage of rheumatoid arthritis can reach about 80%.
Anti-cyclic citrullinated peptide antibody can initially assess whether rheumatoid arthritis will have bone destruction of the joints, patients with higher indexes are prone to bone destruction of the joints and deformation of the joints, and its concentration is also closely related to the duration of rheumatoid arthritis.
Significantly higher anti-cyclic citrullinated peptide antibody suggests that rheumatoid arthritis is more likely, but it is also necessary to combine with the patient’s clinical symptoms, related imaging tests to determine.
It is recommended that patients with elevated anti-cyclic citrullinated peptide antibodies should consult the rheumatology department of a regular hospital for a definitive diagnosis and active treatment under the guidance of a doctor.